Ambrx Biopharma Inc (DELISTED) (AMAM:DL)
27.99
+0.01
(+0.04%)
USD |
NASDAQ |
Mar 06, 16:00
28.00
+0.01
(+0.04%)
After-Hours: 20:00
Ambrx Biopharma Net Income (Quarterly): -22.99M for Sept. 30, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -22.99M |
| June 30, 2023 | -17.83M |
| March 31, 2023 | -15.30M |
| December 31, 2022 | -10.94M |
| Date | Value |
|---|---|
| September 30, 2022 | -15.57M |
| June 30, 2022 | -28.84M |
| March 31, 2022 | -22.65M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-28.84M
Minimum
Jun 2022
-10.94M
Maximum
Dec 2022
-19.16M
Average
-17.83M
Median
Jun 2023
Net Income (Quarterly) Benchmarks
| Johnson & Johnson | 3.255B |
| Axonics Inc | -19.11M |
| Harpoon Therapeutics Inc (DELISTED) | -1.802M |
| Merck & Co Inc | 4.762B |
| RayzeBio inc (DELISTED) | -18.19M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.053M |
| Total Expenses (Quarterly) | 25.68M |
| EPS Diluted (Quarterly) | -0.37 |
| Enterprise Value | 1.542B |
| Profit Margin (Quarterly) | -43.38K% |
| Earnings Yield | -1.82% |
| Normalized Earnings Yield | -1.846 |